SEC Tracker
Get the app

Bone Biologics BBLG

Bone Biologics reports $0 revenue and $617k loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for Q3 2026
  2. Net loss: $617,651 for Q3 2026
  3. Cash and equivalents: $6.09 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Bone Biologics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange QoQ
Operating income and margin−$666K−$808K+18%
Net income−$618K−$774K+20%
Operating cash flow−$532K−$518K−2.7%
Cash$6.09M$4.03M+51%

Similar companies

Companies of similar size in SIC 3842 and related industry codes: the same peer list as the financial tables.

  1. ENvue Medical FEED public float $7M, Jun 30, 2025
  2. SeaStar Medical Holding ICU public float $7M, Jun 30, 2025
  3. Tenon Medical TNON public float $7M, Jun 30, 2025
  4. Sintx Technologies SINT public float $8M, Jun 30, 2025
  5. OSR Health OSRH public float $8M, Dec 31, 2025